



Santa Clara
Family Health Plan

Santa Clara Family Health Plan

Pharmacy & Therapeutics Committee

June 21, 2018
P&T Committee Member Materials



Regular Meeting of the
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan
Pharmacy & Therapeutics Committee

Thursday, June 21, 2018

6:00 PM - 8:00 PM

210 E. Hacienda Avenue Campbell, CA 95008

AGENDA

- | | | | |
|--|---------------|------|---------|
| 1. Introductions | Dr. Lin | 6:00 | 5 min. |
| 2. Public Comment
Members of the public may speak to any item not on the agenda; two minutes per speaker. The Committee reserves the right to limit the duration of public comment period to 30 minutes. | Dr. Lin | 6:05 | 5 min. |
| 3. Meeting Minutes
Review SCFHP 1Q2018 P&T minutes
Possible Action: Approve minutes | Dr. Lin | 6:10 | 3 min. |
| 4. Plan Updates | | | |
| a. CMO Health Plan Updates | Dr. Robertson | 6:13 | 3 min. |
| b. Appeals & Grievances | Mr. Breakbill | 6:16 | 5 min. |
| c. SCFHP Global DUR | Dr. Liu | 6:21 | 4 min. |
| Adjourn to Closed Session
Pursuant to Welfare and Institutions Code Section 14087.36 (w) | | | |
| 5. Metric & Financial Updates | | | |
| a. Membership Report | Dr. Robertson | 6:25 | 2 min. |
| b. Pharmacy Dashboard | Dr. Otomo | 6:27 | 5 min. |
| c. Drug Use Evaluation Results | Dr. McCarty | 6:32 | 3 min. |
| d. Drug Utilization & Spend | Dr. McCarty | 6:35 | 10 min. |
| 6. Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria | | | |
| a. MedImpact 1Q2018 P&T Meetings Minutes | Dr. Huynh | 6:45 | 2 min. |
| b. MedImpact 2Q2018 P&T Part D Actions
Possible Action: Approve MedImpact Minutes & Actions | Dr. Huynh | 6:47 | 3 min. |
| 7. Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria | | | |
| a. Formulary Modifications
Possible Action: Approve formulary recommendations | Dr. Otomo | 6:50 | 5 min. |



- b. DHCS Medi-Cal CDL Updates & Comparability Dr. McCarty 6:55 5 min.
Possible Action: Approve formulary recommendations
- c. Prior Authorization Criteria Dr. Nguyen 7:00 20 min.
Changes to Criteria
1. Diabetic Supplies
2. Androgel
3. Humira
4. Enbrel
Changes to Approval Period
5. Tymlos
6. Differin
7. Dovonex
8. Restasis
9. Enablex
10. Marinol
11. Copaxone
12. Lupron/Lupron Depot
13. Myrbetriq
14. Provigil
15. Lovaza
16. Nebupent
17. Elmiron
18. Symlin
19. Lyrica
20. Exelon
21. Revatio
22. Xenazine
23. Non-Formulary
24. Pain Medications – Terminally Ill
Annual Review – No Changes
25. Epogen
26. Hycet
27. Viroptic
28. Oral Liquids – Non-Formulary
29. Reauthorization
Possible Action: Approve prior authorization criteria
- d. New Drugs and Class Reviews Dr. McCarty 7:20 30 min.
1. CGRP Inhibitor – Migraine
2. Erleada (apalutamide) – Prostate cancer
3. PCSK9 Inhibitor Update (abbreviated)
4. Elagolix– *Informational Only*
5. LutATHERA – *Informational Only*
6. HIV: Symfi, Symfi Lo (EFV/3TC/TDF),
Cimduo (3TC/TDF) – *Informational Only*
Possible Action: Approve formulary recommendations



- e. Line Extensions – *Informational Only*
 - 1. Noctiva (desmopressin)
 - 2. Sinuva (mometasone sinus implant)
 - 3. Sublocade (buprenorphine ER injection)
 - 4. Lonhala Magnair (glycopyrrolate)
 - 5. Firvanq (vancomycin)
 - 6. Bonjesta (doxylamine/B6)
 - 7. Zypitamag (pitavastatin magnesium)
- f. New Indications
 - 1. Blincyto (blinatumomab)
 - 2. Zomacton (somatropin)
 - 3. Zytiga (abiraterone acetate)
 - 4. Imfinzi (durvalumab)
 - 5. Verzenio (abemaciclib)
 - 6. Adcetris (brentuximab)
 - 7. Hizentra (SCIG)
 - 8. IVIG
 - 9. Tassigna (nilotinib)
 - 10. Rubraca (rucaparib)
 - 11. Leukine (sargamostim)
 - 12. Afinitor/Afinitor Disperz (everolimus)
 - 13. Yervoy (ipilimumab)
 - 14. Opdivo (nivolumab)
 - 15. Tagrisso (osimertinib)

Possible Action: Approve formulary recommendations

Reconvene in Open Session

Discussion Items

- | | | | | |
|----|--|-------------|------|---------|
| 8. | Update on New Drugs and Generic Pipeline | Dr. McCarty | 7:50 | 10 min. |
|----|--|-------------|------|---------|

Adjournment

- | | | | | |
|----|--|---------|------|--|
| 9. | Next Meeting Thursday September 20, 2018 | Dr. Lin | 8:00 | |
|----|--|---------|------|--|



Santa Clara
Family Health Plan

Meeting Minutes



Regular Meeting of the
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan
OPEN SESSION - Pharmacy & Therapeutics Committee

Thursday, March 15, 2018
 6:00 PM - 8:00 PM
 210 E. Hacienda Avenue Campbell, CA 95008

MINUTES

Voting Committee Members	Specialty	Present (Y or N)
Jimmy Lin, MD	Internal Medicine	Y
Hao Bui, BS, PharmD	Community Pharmacy (Walgreens)	N
Minh Thai, MD	Family Practice	Y
Amara Balakrishnan, MD	Pediatrics	Y
Peter Nguyen, MD	Family Practice	Y
Jesse Parashar-Rokicki, MD	Family Practice	Y
Narinder Singh, PharmD	Health System Pharmacy (SCVMC)	N
Ali Alkoraishi, MD	Adult & Child Psychiatry	Y
Dolly Goel, MD	VHP Chief Medical Officer	Y
Xuan Cung, PharmD	Pharmacy Supervisor (VHP)	N
Johanna Liu, PharmD, MBA	SCFHP Director of Quality and Pharmacy	Y
Jeff Robertson, MD	SCFHP Chief Medical Officer	Y

Non-Voting Committee Members	Specialty	Present (Y or N)
Lily Boris, MD	SCFHP Medical Director	N
Caroline Alexander	SCFHP Administrative Assistant, Medical Management	N
Tami Otomo, PharmD	SCFHP Clinical Pharmacist	Y
Duyen Nguyen, PharmD	SCFHP Clinical Pharmacist	Y
Dang Huynh, PharmD	SCFHP Pharmacy Manager	Y
Amy McCarty, PharmD	MedImpact Clinical Program Manager	Y
Tiffany Pham, CPhT	SCFHP Pharmacy Coordinator	Y

	Topic and Discussion	Follow-Up Action
1	Introductions The meeting convened at 6:09 PM.	
2	Public Comment No public comment.	
3	Past Meeting Minutes The SCFHP 4Q2017 P&T Minutes from December 14, 2017 were reviewed by the Committee as submitted.	Upon motion duly made and seconded, the SCFHP 4Q2017 P&T Minutes from December 14, 2017 were approved as



		submitted and will be forwarded to the QI Committee and Board of Directors.
4	Plan Updates	
	<p>Health Plan Updates Dr. Robertson presented the slow, but steady decline in Medi-Cal members possibly due to the actions of immigration rates. The annual DHCS audit will be held next month from 4/9-4/20 at the health plan.</p> <p>Dr. Peter Nguyen asked if the steady decline was affecting the Medicare or Medi-Cal line of business. Dr. Robertson clarified that this is affecting the Medi-Cal line of business, and Medicare line of business is increasing.</p>	
	<p>Appeals & Grievances Dr. Huynh presented the Appeals & Grievances report Q4 2017. There was a decline in Medi-Cal appeals after a short increase due to a change in process. Q4 2017 53% overturn rate, 27% upheld, 5% withdrawn. For CalMediConnect (CMC), Q3-Q4 Part C&D redeterminations have remained steady. Redeterminations Q4, 39% overturned, 56% upheld, 0% withdrawn.</p> <p>Dr. Peter Nguyen asked if the percentages are normal compared to other health plans, and Dr. Robertson clarified that SCFHP does not have available data to benchmark our results to.</p>	
	<p>SCFHP Pharmacy Dept. Policies: Dr. Huynh presented the Pharmacy Dept. Policies as followed:</p> <ol style="list-style-type: none"> 1. PH01 Pharmacy and Therapeutics Committee 2. PH02 Formulary Development and Guideline Management 3. PH03 Prior Authorization 4. PH04 Pharmacy Clinical Programs and Quality Monitoring 5. PH05 Continuity of Care for Pharmacy Services 6. PH06 Pharmacy Communications 7. PH07 Drug Recalls 8. PH08 Pain Management Drugs for Terminally Ill 9. PH09 Medications for Members with Behavioral Health Conditions – <i>Revised</i> 10. PH10 Cal MediConnect Part D Transition 11. PH11 340B Program Compliance 12. PH14 Medications for Cancer Clinical Trial 	Upon motion duly made and seconded, the Pharmacy Dept. Policies were approved as presented.
	<p>Adjourn to Closed Session Committee adjourned to closed session at 6:20 p.m. to discuss the following items: Membership Report, Pharmacy Dashboard, Drug Use</p>	



	Evaluation Results, Drug Utilization & Spend, Recommendations for Changes to SCFHP Cal MediConnect Formulary and Prior Authorization Criteria, Recommendations for changes to Medi-Cal and Healthy Kids Formulary and Prior Authorization Criteria, DHCS Medi-Cal CDL Updates & Comparability, and New Drugs.	
5	Metrics & Financial Updates	
	Membership Report Dr. Robertson presented the membership report.	
	Pharmacy Dashboard Dr. Otomo presented the Pharmacy Dashboard.	
	Drug Utilization & Spend Review Dr. McCarty presented the Drug Use Evaluation Results.	
	Drug Utilization & Spend Review Dr. McCarty presented the Spend and Trend Overview.	
6	Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria	
	Dr. Huynh presented an overview of the MedImpact 4Q2017 P&T minutes as well as the MedImpact 1Q2018 P&T Part D Actions.	Upon motion duly made and seconded the MedImpact 4Q2017 P&T Minutes, and MedImpact 1Q2018 P&T Part D Actions were approved as submitted.
7	Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria	
	Formulary Modifications Dr. Otomo presented the formulary changes since the last P&T meeting.	Upon motion duly made and seconded, formulary modifications were approved as presented.
	DHCS Medi-Cal CDL Updates & Comparability Dr. McCarty presented DHCS Medi-Cal CDL Updates & Comparability.	Upon motion duly made and seconded, prior authorization criteria were approved as requested.
	Prior Authorization Criteria Dr. Duyen Nguyen presented the following PA criteria for approval by the committee: <ol style="list-style-type: none"> 1. Zetia 2. Glatiramer acetate 	Upon motion duly made and seconded, prior authorization criteria were approved with the requested deletion from the Oncology PA criteria.



	<ol style="list-style-type: none">3. Oncology4. Quantity Limit	
	<p>New Drugs and Class Reviews</p> <p>Dr. McCarty presented the following new drug reviews:</p> <ol style="list-style-type: none">1. Diabetes Update SGLT-2 inhibitors, Rapid Acting Insulin.2. Hemlibra.3. Psoriasis Update – Tildrakizumab.	Upon motion duly made and seconded, all recommendations were approved as presented.
	<p>Reconvene in Open Session</p> <p>Committee reconvened to open session at 7:44 p.m.</p>	
8	Discussion Items	
	<p>Update on New Drugs and Generic Pipeline</p> <p>Dr. McCarty presented the generic pipeline for 1Q2018. High impact drugs: ProAir HFA, Tracleer, Byetta, Sensipar and medium/low impact drugs: Forfivo, XL, Viread, Solodyn, Treximet, Zortress, and Sustiva.</p>	
9	Adjournment at 7:49 PM	



Santa Clara
Family Health Plan

Plan Updates



Santa Clara
Family Health Plan

The Spirit of Care

P&T Committee

Grievance and Appeals Q1 2018 Report

June 21, 2018



Medi-Cal & Healthy Kids

January						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

February						
S	M	T	W	T	F	S
		1	2	3	4	
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

March						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

April						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

May						
S	M	T	W	T	F	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30						

June						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
						W

July						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

August						
S	M	T	W	T	F	S
		1	2	3	4	
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

September						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

October						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

November						
S	M	T	W	T	F	S
		1	2	3	4	
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		


December						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
						W




Q1 2018



Q4 2017-Q1 2018: Medi-Cal Appeals




Q1 2018 Medi-Cal Pharmacy Appeals



Overturned Upheld Partially Favorable Withdrawn Dismissed In Process



Medi-Cal Rates per 1000: Rx Appeals



Cal Medi-Connect

January						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

February						
S	M	T	W	T	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

March						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	31

April						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

May						
S	M	T	W	T	F	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	

June						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						

July						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

August						
S	M	T	W	T	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

September						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

October						
S	M	T	W	T	F	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

November						
S	M	T	W	T	F	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		


December						
S	M	T	W	T	F	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						




Q1 2018



Q4 2017-Q1 2018: Part C&D Appeals



CMC Part D Redeterminations by Determination Q1 2018



■ Overturned ■ Upheld ■ Partially Favorable ■ Dismissed





Santa Clara
Family Health Plan

Update on New Drugs and Generic Pipeline

Recently Approved - High Interest and Impact



February 2018 – May 8th 2018

Entity	Disease State	FDA Approval	Route	Therapeutic Role	Net PMPM
Symdeko (tezacaftor/ ivacaftor)	Cystic Fibrosis	Feb 12, 2018	Oral	Competitor	\$0.001 – \$0.002
Erleada (apalutamide)	Prostate Cancer	Feb 14, 2018	Oral	Breakthrough Therapy	\$0.03 – \$0.04
Trogarzo (ibalizumab-uiyk)	Human Immuno- deficiency Virus (HIV)	Mar 6, 2018	IV	Additive	\$0.06 – \$0.08
Ilumya (tildrakizumab)	Plaque Psoriasis	Mar 21, 2018	SQ	Competitor	\$0.00
Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo]	Factor Xa Reversal Agent	May 3, 2018	IV	Breakthrough Therapy	\$0.05 – \$0.08
Aimovig (erenumab)	Migraine	May 17, 2018	SQ	Additive	\$0.06 – \$0.30

 = Medical Cost

High Interest and Impact Pipeline Agents



2H2018

Entity	Disease State	Anticipated FDA Decision	Route	Therapeutic Role	Net PMPM
Epidiolex (cannabidiol)	Dravet syndrome, Lennox-Gastaut syndrome	June 27 th , 2018	Oral	Additive	\$0.009 – \$0.013
baricitinib	Rheumatoid Arthritis (RA)	2nd Quarter 2018	Oral	Competitor	\$0.00
lorlatinib	ALK+ Non-Small Cell Lung Cancer (NSCLC)	August 2018	Oral	Competitor	\$0.04 - \$0.06

 = Medical Cost

Generic Pipeline 2Q18

HIGH IMPACT

April 2018
Nuvaring

May 2018
Adcirca

June 2018
Remodulin

July 2018
Letairis

August 2018
Ampyra

Sept 2018
Cialis

2018
Tracleer*
Byetta
Kaletra

2Q18

3Q18

4Q18

2Q18
Delzicol

June 2018
Abstral
Onexton

1H18
Zortress

July 2018
Acanya

3Q18
Levitra

Sept 2018
Moviprep

2H18
Flector

4Q18
Proventil HFA
Rapaflo

2018
Androgel (1.62%)

MEDIUM /LOW IMPACT

**NO exclusivity*